VIVUS' Qnexa Shows Significantly Improved Blood Sugar Control Through Weight Loss In Patients With Type ...( - Year-Long Phase 2 Diabetes Study Re...),Health

- Year-Long Phase 2 Diabetes Study Results Presented at ADA Annual Meeting -

NEW ORLEANS, June 8 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS), a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health, today announced that data from a year-long phase 2 trial (DM-230) evaluating Qnexa(TM) in patients with type 2 diabetes are being highlighted in an oral podium presentation at the American Diabetes Association (ADA) 69th Scientific Sessions (abstract 361-OR). The study demonstrated that Qnexa, an investigational new drug, significantly reduced patients' hemoglobin A1c (HbA1c) -- a key indicator of blood sugar control -- and helped patients achieve and maintain significant weight loss. The study also showed that Qnexa had a positive impact on other risk factors associated with diseases prevalent in people living with diabetes.

"While it is widely known that type 2 diabetes can be treated through weight loss, the currently approved weight loss therapies have limitations. The optimal diabetes therapy will not only enable patients to control their blood sugar by lowering glucose levels to the desired range, but will also help patients achieve meaningful weight loss," said W. Timothy Garvey, MD, Professor of Medicine and Chair of the Department of Nutrition Sciences at the University of Alabama at Birmingham and presenter. "The HbA1c reduction seen in this study of Qnexa is significant. The 9.4 percent weight loss observed in these patients -- on average more than 20 pounds -- is compelling, not only because of the amount, but more importantly the ability to maintain the weight loss over a year. These results suggest that Qnexa has the potential to play an important role in diabetes management with respect to blood sugar control and susta
'/>"/>